HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Anthracycline-induced cardiotoxicity: report of fatal cases].

AbstractBACKGROUND:
Anthracyclines are effective drugs in pediatrics cancer treatment. However, anthracycline-induced cardiotoxicity (AIC) is a serious adverse drug reaction that affects the survival in patients treated for childhood cancer.
CLINICAL CASES:
Case 1: Nine-year-old girl with stage IV Hodgkin lymphoma with 12 epirubicin doses and a cumulative dose of 576 mg/m2. After last chemotherapy dose, the patient was admitted with systemic inflammatory response, asthenia and adinamia. Echocardiography: LVEF of 22%, SF 11% and moderate mitral regurgitation. Patient died 2 days after diagnosed with dilated cardiomyopathy secondary to anthracyclines. Case 2: Fifteen-year-old girl with stage IV Burkitt lymphoma with two epirubicin doses and a cumulative dose of 90 mg/m2. After the last cycle, the patient developed several infectious foci. Echocardiography: LVEF of 49%, SF 20% and dilated left ventricle with septal flattening. Patient died 13 days after diagnosis of dilated cardiomyopathy by anthracyclines.
CONCLUSION:
AIC is a problem in pediatric patients receiving anthracyclines, monitoring is essential to detect the onset of cardiac damage to provide an intervention to prevent heart failure progress.
AuthorsJessica Liliana Vargas-Neri, Osvaldo Daniel Castelán-Martínez, María de Jesús Estrada-Loza, Yadira Betanzos-Cabrera, Rodolfo Rivas-Ruiz
JournalRevista medica del Instituto Mexicano del Seguro Social (Rev Med Inst Mex Seguro Soc) 2016 May-Jun Vol. 54 Issue 3 Pg. 404-8 ISSN: 2448-5667 [Electronic] Mexico
Vernacular TitleCardiotoxicidad inducida por antraciclinas. Reporte de casos fatales.
PMID27100990 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibiotics, Antineoplastic
  • Epirubicin
Topics
  • Adolescent
  • Antibiotics, Antineoplastic (adverse effects)
  • Cardiomyopathy, Dilated (chemically induced, diagnosis)
  • Cardiotoxicity
  • Child
  • Epirubicin (adverse effects)
  • Fatal Outcome
  • Female
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: